CEPI is an innovative global partnership between public, private, philanthropic, and civil society organisations launched in Davos in 2017 to develop vaccines to stop future epidemics. Our mission is to accelerate the development of vaccines and other biologic countermeasures against epidemic and pandemic threats so they can be accessible to all people in need. CEPI takes an end-to-end approach, operating as both a funder and a facilitator. We focus on vaccine development, licensure, and manufacturing while supporting the efforts of our partners in vaccine discovery and delivery. Our headquarters are in Oslo, Norway, and we have offices in London, UK, and Washington DC, USA. We also work closely with public-sector, private-sector, and civil-society partners around the world. Close collaboration with global partners are crucial to ensure the success of our work. Therefore, we will support coordinating activities to improve our collective response to epidemics, strengthening capacity in countries at risk, and advancing the regulatory science that governs product development. | CEPI is an innovative partnership between public, private, philanthropic, and civil organizations, launched at Davos in 2017, to accelerate and invest in the development of vaccines and other biologic countermeasures against epidemic and pandemic threats so they can be accessible to all people in need. CEPI’s 2022-2026 plan, known as CEPI 2.0, is helping the world to make the scientific progress needed to respond to the next Disease X threat with a new vaccine in just 100 days. This goal is known as the 100 Days Mission. CEPI’s pandemic plan aims to substantially reduce or even eliminate the future risk of pandemics and epidemics. The plan is set around three pillars: prepare for known threats; transform the response to the next novel outbreak; and connect and enhance global collaboration to strengthen global preparedness. Our Calls for Proposals invite innovators and developers worldwide to apply to our scientific programs for funding to advance the development and manufacture of vaccines and tools against epidemic and pandemic threats.
Center for Biotechnology at Stony Brook University
Established in 1983, the Center for Biotechnology (CFB) at Stony Brook University is an Empire State Development Division of Science, Technology and Innovation (NYSTAR) Center for Advanced Technology. The Center for Biotechnology serves as an important catalyst in the development of new biomedical technology and emerging companies in New York State. Through groundbreaking initiatives, the CFB supports technology commercialization and company formation by bridging the gap between discovery and commercial success and training the next generation of biomedical leaders. The Center for Biotechnology also supports New York’s biotechnology industry by providing access to scientific and business expertise and creating strategic infrastructure that promotes the growth of the life sciences industry in the state. The CFB has contributed to the development of more than a dozen FDA approved products including ReoPro®, Xiaflex®, Oracea®, Cavistat®, V3D®-Colon Virtual Colonoscopy and Exogen® Bone Healing System, among others, as well as supported the formation or development of dozens of emerging bioscience companies.
Business Oregon
Life Science/Bioscience is one of Oregon’s leading Target Industries, and has become an emerging, competitive segment of the state’s economy. Oregon is also one of only six states that has been chosen to receive US Federal funding to develop a Microfluidics Hub called CorMic in Corvallis, Oregon. This represents the possibility of Billions of dollars in future Life Science Development for Oregon. Due to a recent expansion and influx of firms, like Genentech (a Roche subsidiary) and Twist Bioscience, Oregon’s bio community is growing faster and gaining more market share vs. many other U.S. states. With nearly 1,500 establishments, Oregon’s Bio market produced $15.7 billion (2022) in economic output, and nearly $1 billion in pharmaceuticals, medicine, and medical equipment. As one of the fastest growing parts of Oregon’s innovation economy, bioscience is generating exciting new research, life-changing products, and attracting increased amounts of venture capital, and foreign direct investment. | Business Oregon is the State of Oregon’s economic development agency. Bioscience is one of Oregon’s leading Target Industries and has become an emerging, competitive segment of Oregon’s economy. Major Life Science/Bioscience firms like Genentech (a Roche Subsidiary), Lonza, ThermoFisher Scientific, and Twist bioscience all have significant facilities in Oregon, and our bio community is growing faster and gaining more market share vs. many other U.S. states. With nearly 2,000 companies and 75,000 employees, Oregon’s Bioscience market produced $21.2 billion (2023) in total economic output, and $5.6 billion in pharmaceutical, medicine, and medical equipment exports. As one of the fastest-growing parts of Oregon’s innovation economy, bioscience is generating exciting new research, and life-changing products, and attracting increased amounts of venture capital, and foreign direct investment. Our core functions include business retention, expansion, and recruitment; export promotion and international trade; industry research and development and entrepreneurship; small business assistance; rural community development and infrastructure financing; and support for arts and cultural organizations.
Brazilian Center for Research – CNPEM
CNPEM is a sophisticated and ebullient environment for research and development that is the only one of its kind in Brazil and found in only a few scientific centers in the world. The Center private, non-profit organization overseen by the Ministry of Science, Technology, and Innovation (MCTI). The Center is home to Sirius, the most complex project in Brazilian science and one of the world’s most advanced synchrotron light sources. CNPEM comprises highly specialized multi-thematic teams, globally competitive lab infrastructure that is open to the scientific community, strategic lines of research, innovative projects in partnerships with the productive sector, and training programs for researchers and students. CNPEM is an environment driven by research into solutions that impact the areas of health, energy and renewable materials, agro environmental and engineering. | The Brazilian Center for Research in Energy and Materials (CNPEM) is home to a state-of-the-art, multi-user and multidisciplinary scientific environment. A social organization overseen by the Ministry of Science, Technology and Innovation, CNPEM powers Brazil’s science with cutting-edge labs like Sirius, tackling global challenges in health, renewable materials, energy & sustainability.
BioVation RLP
The Life Science Center Mainz, as an innovation, technology, and startup center for biotechnology and life sciences, supports the establishment of a supra-regional platform for biotechnology, life sciences, and medical technology on behalf of the Ministry of Economic, Transportation, Agriculture, and Viniculture in Rhineland-Palatinate. For this purpose, a new, independent business unit, BioVation RLP, has been established. We promote partnerships between companies, research institutions, and universities to leverage synergies and drive innovation. We initiate interdisciplinary projects that enable the exchange of ideas and technologies across different industries, fostering new solutions. We actively promote the strengths and potential of Rhineland-Palatinate as a leading location for biotechnology and life sciences to attract talents and investors. We develop modular offerings at the LZM BioCampus tailor-made to meet the specific requirements of the biotechnology, life sciences, and medical technology sectors. In the future, we are planning to build up strategic and cross-industry networks for an innovative, sustainable economy based on renewable resources, resource-efficient processes, and material flow management.
BioPark Regensburg GmbH
BioPark Regensburg GmbH is an enterprise of the City of Regensburg and part of the promotion of the economy. Our key task is promoting biotechnology, medical engineering, diagnostics and analytics as well as healthcare at the location and in the region. To do this for one we operate a three laboratory building with an area of a total of 18,000 m2 on the grounds of the University of Regensburg, in which there are currently 35 leaseholders with 676 employees. For another we coordinate the active cluster management of the Regensburg Bioregion from here with at this time 66 companies and 5,340 employees in East Bavaria. The BioPark Regensburg GmbH is the management and administrative headquarters of the biotechnology research cluster known as BioRegio Regensburg in East Bavaria. Located strategically at the northernmost point of the Danube, in the Austrian-Czech-German triangle, the area is regarded as the gateway to the East of the extended European Union. Currently 66 firms with 5,340 employees are active in the field of life sciences in BioRegio Regensburg. As a result it has become the most important region for Biotechnology in Bavaria, second only to Munich. More than 50 businesses and institutions, five hospitals and two universities. The growing significance of this industry for the future of the cathedral city and the region of Upper Palatinate was documented by an assessment of the cluster in 2021. Since the last count in 2011 the number of employees in the healthcare industry has risen by around 34%. In 2020 there were a total of 21,600 employees with social security insurance working in the healthcare field in the Regensburg Region. 80% of these are in the City of Regensburg and 20% in the Regensburg District. With 11,715 employees over half of these work in the 5 hospitals in the city and the district. In the field of local doctors there were 4,087 people employed at last count. Also in inpatient and outpatient care the numbers of employees rose by 34% to 4,123. There are currently 831 companies in the health sector in the Regensburg area, 60% of them in the city and 40% in the district. These generated sales of € 2.7 billion in 2019, which is almost twice as much as in 2011 with a rate of increase of 92.9% and corresponds to an annual growth rate of 7.6%. | BioPark Regensburg GmbH is an enterprise of the City of Regensburg and part of the promotion of the economy. Our key task is promoting biotechnology, medical engineering, diagnostics and analytics as well as healthcare at the location and in the region. To do this for one we operate a three laboratory building with an area of a total of 18,000 m2 on the grounds of the University of Regensburg, in which there are currently 37 leaseholders with 683 employees. For another we coordinate the active cluster management of the Regensburg Bioregion from here with at this time 66 companies and 5,671 employees in East Bavaria, Germany. ince the last count in 2011 the number of employees in the healthcare industry has risen by around 34%. In 2020 there were a total of 21,600 employees with social security insurance working in the healthcare field in the Regensburg Region. 80% of these are in the City of Regensburg and 20% in the Regensburg District. With 11,715 employees over half of these work in the 5 hospitals in the city and the district. In the field of local doctors there were 4,087 people employed at last count. Also in inpatient and outpatient care the numbers of employees rose by 34% to 4,123. There are currently 831 companies in the health sector in the Regensburg area, 60% of them in the city and 40% in the district. These generated sales of € 2.7 billion in 2019, which is almost twice as much as in 2011 with a rate of increase of 92.9% and corresponds to an annual growth rate of 7.6%.
BioMedSA: San Antonio
San Antonio is the 7th largest city in the US and the healthcare and bioscience sector contributes the largest economic contribution in the region. San Antonio is home to the largest military health complex in the US. When combined with the academic and independent research institutions and a collaborative culture, a powerhouse of bioscience capability is formed. The business-friendly climate, low commute times, low cost-of-living, and high quality of life make San Antonio the ideal location for biomedical work. BioMedSA is a non-profit organization dedicated to the growth of the healthcare and bioscience sector in San Antonio and the surrounding region. We accomplish our mission by empowering companies to succeed, promoting the region, and creating actions for growth that benefit the industry and community-at-large. As the hub of the ecosystem, we make vital connections to resources and build collaborations. | BioMedSA is a member-driven hub for the life science industry in San Antonio with the mission to accelerate the growth of the healthcare and bioscience sector, create regional economic benefit, and contribute to the health of San Antonio and beyond. | BioMedSA was founded in 2005 to accelerate growth of the healthcare and bioscience sector, create regional economic benefit, and contribute to the health of San Antonio and beyond by establishing San Antonio as a leader in healthcare and bioscience. BioMedSA serves as the hub for the healthcare and bioscience industry in San Antonio and the surrounding region, connecting people, opportunities and resources, facilitating key collaborations, advocating for industry needs, convening industry leader forums to conquer challenges, and promoting the City of Science and Health. | x
biomindz
About us Over the years, Mainz has developed a global reputation as a successful life sciences and biotechnology hub and today provides an ideal environment for both fundamental and application-based research as well as businesses. The hub’s primary emphasis lies on medical biotechnology and life sciences, but we are open for other research areas and technologies. biomindz was founded as a municipally owned company. We work on behalf of the city of Mainz closely with other stakeholders from the city of Mainz and the state of Rhineland-Palatinate. Our primary task is to support the ongoing development and promotion of the life sciences and biotechnology sector in Mainz. We are looking for researchers, startups and companies that are interested to establish and grow in Mainz, Rhineland-Palatinate, Germany. We would like to connect with potential network partners and/or investors for the ecosystem, particularly for our expanding life science and biotech campus. As we are very early in the development of our hub, we are not that much looking for companies that would like to inform about their services for an already existing local network.
BioM Biotech Cluster Development GmbH
BioM has been the development and management organization of the Munich Biotechnology Cluster since 1997. The BioM Cluster encompasses the Greater Munich area and today includes around 450 biotechnology and pharmaceutical companies as well as associated service providers. The core competence of the region is the development of innovative therapeutics, diagnostics, and underlying technologies, especially for personalized medicine. | BioM has been the network organization of the biotechnology industry in Munich and Bavaria for over 25 years, commissioned by the Bavarian Ministry of Economic Affairs. As a non-profit organization, BioM creates a unique ecosystem in medicine and biotechnology for innovation, growth and value creation in Bavaria. To achieve this, we connect all the relevant partners and support Bavarian biotech companies. BioM provides comprehensive advice and special coaching, training and mentoring programs especially for prospective company founders. With its incubator MAxL (Munich Accelerator Life Sciences & Medicine), BioM also offers optimal conditions for pre-seed projects and early-stage start-ups in the biotech and healthtech sector. BioM has also been coordinating the m4 Award pre-seed competition in the field of biomedicine since 2011, which is funded by the Bavarian Ministry of Economic Affairs with a total of 2.5 million euros. BioM has so far supported over 250 start-ups. In addition, BioM offers a variety of workshops, training courses and events on industry-specific topics. The Bavarian Biotech Cluster comprises over 520 biotechnology and pharmaceutical companies as well as associated service providers. The core competence of the region is the development of innovative therapeutics, diagnostics and the underlying technologies, especially for personalized medicine.
BioLeap
Non-profif Organization